87 results about "Structural protein" patented technology

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

A provided self-replicating mRNA is transcribed from an alphavirus backbone vector. The alphavirus backbone vector comprises gene sequences of alphavirus non-structural proteins nsP2, nsP3, nsP4, and mutated nsP1. A cysteine at position 492 of the mutated nsP1 is mutated into serine. The self-replicating mRNA has a higher expression level and a longer expression time for a target gene. The self-replicating mRNA is used for expressing IMP3, and can be prepared into a vaccine having good preventive and therapeutic effects on IMP3-positive tumors. Therefore, the present invention has good application prospects in drug and vaccine development.

The application discloses a preparation method of a decellularized matrix and a product prepared by the method. The preparation method comprises the following steps: (1) washing a mammalian soft tissue to remove blood, lipids and impurities, and cutting the tissue into pieces with a thickness of 1-10 mm; (2) soaking the pieces in solution 1 for 6-48 h, and then soaking the pieces in solution 2 for 0.1-1 h; (3) treating the pieces in an ultrasonic water bath under the condition of a frequency of 20-40 kHz for 5-30 min; (4) water-bathing the pieces at 55-65 DEG C for 10-30 min; (5) sequentially washing the tissue with deionized water, a PBS buffer and ethanol, and washing the tissue with each solution for 1-3 times, each time for 10-30 min; and (6) freeze-drying the decellularized matrix material, and crushing the material at-80 DEG C to-20 DEG C to obtain a decellularized matrix powder. The preparation method significantly improves the cell component removal efficiency, effectively protects structural proteins such as collagen from being degraded in the freeze-drying and crushing processes, and ensures the integrity of the matrix in the aspects of morphology, structure and function, thereby providing a structural support and biological signal support for subsequent tissue repair.

The present disclosure relates to a novel system for the generation and use of hybrid alpha-pseudoviruses against ribose viruses. A hybrid ribose virus-alpha-pseudovirus (HRAP) presents a novel particle having an RNA genome derived from an alphavirus and a structural protein of a virus in the ribose virus field. The HRAP particle is formed by assembling structural proteins crossing different riboviridae and can be used for vaccine development, antiviral drug screening, neutralization test, treatment or immune response starting and the like.

This invention belongs to the field of genetic engineering. By introducing a TC tag between amino acids 199 and 200 of the wild-type bluetongue virus non-structural protein NS2, a recombinant virus was rescued. Analysis of viral plaques and growth curves revealed that the recombinant virus formed plaques of similar size to the wild-type virus, and their growth curves showed no significant difference. Immunofluorescence and FlasH-EDT2 staining of NS2 showed that the fluorescence of NS2 labeled with anti-NS2 antibody overlapped with that labeled with FlasH-EDT2. Three-dimensional imaging of FlasH-EDT2-labeled NS2 revealed that the viral inclusion bodies exhibited fluorescence around the periphery but no fluorescence inside, displaying an overall "core-shell" hierarchical structure. This recombinant bluetongue virus can be used for tracing and localizing NS2 protein and viral inclusion bodies in living cells, and can also be applied to BTV neutralization assays, antiviral drug screening, and other related research.

This invention discloses an anti-phage system based on ESCRT-III and its applications, relating to the field of biotechnology. This invention utilizes the coding genes for two structural proteins of the Hoda_Snf7_1 and Hoda_Snf7_2 from the Hoda archaea ESCRT-III. Hoda_ snf7_1 and Hoda_snf7_2 This invention is applied to antiphage systems. Compared with existing technologies, the main advantages of the antiphage system of this invention are: (1) it consists of only two genes, making system construction simple and quick; (2) it is composed of structural proteins, making it less prone to losing antiphage activity due to gene mutations; (3) it has a broad-spectrum antiphage effect; and (4) it does not affect the normal growth of host bacteria. This system expands the understanding of antiphage systems and provides new ideas and technical means for preventing and controlling phage contamination in industrial microbial production processes.

The invention belongs to the technical field of food processing, and particularly relates to a preparation method and application of a meat anti-freezing adhesive containing plant polyphenol and ice structuring protein. The meat adhesive comprises the following components in percentage by mass: 0.1%-5% of ice structuring protein, 0.5%-10% of plant polyphenol, 9%-14% of glutamine transaminase, 30%-60% of sodium caseinate, 5%-20% of gelatin, 2%-5% of sodium tripolyphosphate, 2%-5% of sodium pyrophosphate and 10%-25% of maltodextrin. The invention provides a natural, efficient and multifunctional meat anti-freezing adhesive which can effectively inhibit ice crystal growth and recrystallization in the freezing process, reduce juice loss, firmly bond meat pieces and delay oxidation discoloration.

The invention provides a norovirus genome splicing method and device, a medium and a product. The method comprises the following steps: acquiring a norovirus gene database, wherein the norovirus gene database comprises a non-structural protein coding region sub-library and a capsid protein coding region sub-library; obtaining original sequencing data; performing quality control on the original sequencing data to obtain screened sequencing data; comparing and assembling the screened sequencing data with the non-structural protein coding region sub-library, and determining at least one first recombinant coding region; and comparing and assembling the screened sequencing data with the capsid protein coding region sub-library, and determining at least one second recombinant coding region, and splicing the at least one first recombinant coding region and the at least one second recombinant coding region to obtain a recombinant genome sequence. Through the technical scheme disclosed by the invention, efficient and accurate splicing of the recombinant norovirus genome sequence is realized, and the assembly accuracy and efficiency of the recombinant norovirus genome sequence are improved.

The invention relates to the technical field of biology, and discloses a Zika virus non-structural protein 1 functional site and application thereof in design of a Zika virus attenuated strain. According to the invention, a new Zika virus virulence site is innovatively found, and a basis is provided for research of Zika virus and research and development work of related drugs. The invention also provides an attenuated mutant strain constructed on the basis of the virulence site, and the attenuated mutant strain has obvious attenuated characteristics and higher genetic stability, and can be used as an alternative strain of a Zika virus attenuated live vaccine.

The invention discloses a method for secretory expression of recombinant mechanical structural protein by using escherichia coli and application, and relates to the field of bioengineering. According to the method, signal peptides are introduced to the N end of recombinant mechanical structural proteins, and the signal peptides, namely OmpA, PelB, PhoA, DsbA and STII, capable of guiding different recombinant mechanical structural proteins to secrete and express are screened from six natural signal peptides from escherichia coli and other species. Meanwhile, the yield of extracellular protein is further improved by combining an amino acid tRNA supplement strategy. According to the method, the recombinant escherichia coli strain capable of efficiently secreting and expressing the mechanical structure protein can be obtained, the downstream purification process is simplified, and the method has important application value.

The application discloses a recombinant FCV antigen and a construction method and application thereof. The construction method of the recombinant FCV antigen comprises the following steps: fusing a T cell epitope coding sequence of a non-structural protein NS7 of FCV and a coding sequence of a SpyTag peptide segment through a coding sequence of a linker, then cloning into a baculovirus transfer vector to obtain a recombinant plasmid, and finally integrating the T cell epitope coding sequence into Bacmid through Tn7 transposition to finally obtain the recombinant FCV antigen. The application selects NS7 as a core immunogen, guides the immune system to produce a high cellular immune response, and thus makes up for the deficiency of an existing vaccine in clearing intracellular viruses; meanwhile, a specific T cell epitope is selected in the sequence of NS7 as an immunogen, which can avoid the immunological escape caused by the variation degree of antigens among different strains and virus antigen drift, and thus provides broader protection.

Provided herein are stoichiometric Gas Vesicle Expression Systems (GVES), sets of polynucleotide constructs, and related vectors, cells, compositions, and methods configured for robust expression of Gas Vesicle Gene Clusters (GVGCs) in mammalian cells, particularly primary and immune cells. The GVES comprises distinct gene modules for the primary structural protein (gvpA / B) and assembly factors (AF1, AF2), operably configured to achieve a stoichiometric expression ratio, quantified by Dosage Index (DI), wherein the gvpA / B module is expressed at least 2-fold higher than the AF1 and AF2 modules.

The invention belongs to the technical field of animal reproductive biology and cell engineering, and particularly relates to a fluorescence labeling expression system for visualizing an oocyte nucleus maturation process and application of the fluorescence labeling expression system. The fluorescence labeling expression system comprises an eukaryotic expression vector pVenus-LMNB1; the eukaryotic expression vector pVenus-LMNB1 comprises a nucleotide sequence for coding the fusion protein Venus-LMNB1. According to the invention, a nuclear fiber layer protein stably expressed on a nuclear membrane is selected as a research object, a eukaryotic expression vector pVenus-LMNB1 is constructed by using a molecular cloning technology, an LMNB1 gene containing a green fluorescent label Venus is overexpressed in a porcine oocyte by using a microinjection technology, fluorescent protein labeling of a structural protein on the nuclear membrane is utilized, and the expression vector pVenus-LMNB1 is constructed. The expression positioning condition of the LMNB1 in the maturation process of the porcine oocytes is observed, and a powerful tool is provided for development of in-vitro culture related researches of the porcine oocytes.

The present invention is in the field of Nipah virus (NiV) structural protein. Particularly, the invention provides structure based stabilized Nipah virus (NiV) structural protein designing and uses thereof.

The present application relates to the technical field of probiotic microcapsules, and particularly relates to a high-activity composite wall material probiotic microcapsule and a preparation method thereof.The high-activity composite wall material probiotic microcapsule comprises a composite wall material and a core material, and the raw material of the composite wall material comprises konjac glucomannan, soybean protein isolate and nano titanium dioxide, and the mass ratio of the konjac glucomannan, the soybean protein isolate and the nano titanium dioxide is (3-5):(2-4):(0.5-1.5).By constructing the composite wall material system composed of the konjac glucomannan, the soybean protein isolate and the nano titanium dioxide, the polysaccharide skeleton structure, the protein flexible network and the nano particle function enhancement effect are mutually synergistic, so that the mechanical properties, the structural stability and the environmental tolerance of the microcapsule are significantly improved.Meanwhile, the nano titanium dioxide endows the microcapsule with excellent antibacterial properties and ultraviolet shielding capacity, and can effectively inhibit the influence of external harmful microorganisms and reduce the damage of light to the activity of the probiotic.

The invention belongs to the field of gene engineering, and particularly relates to application of chikungunya virus structural protein in improvement of pseudovirus stability, a construction method of the chikungunya virus structural protein and vaccines, antibody evaluation and in-vivo gene therapy products. The method comprises the following steps: constructing a human codon optimized Asian strain CHIKV-E3 + E2 + 6K + E1 structural protein eukaryotic vector, and designing two types of binder expression plasmids of targeted T cells; the vector, a psPAX2 helper plasmid and a lentivirus target vector containing an SFFV promoter and a ZsGreen reporter gene (or a CAR therapeutic gene) are co-transformed into a 293T cell, and the lentivirus is prepared through culture, filtration and centrifugation. The lentivirus can efficiently infect Jurkat cells and activate human T cells, obviously reduces the infection efficiency on 293T cells so as to reduce the off-target effect, has excellent stability in human serum, and provides a safe and efficient gene delivery tool for in-vivo CAR-T therapy.

Synthetic peptides mimicking the nsp10 sequence in the region interacting with nsp16 capable of penetrating cell membranes and inhibiting SARS-CoV-2 replication for the treatment of moderate to severe COVID-19. The invention relates to peptides inhibiting SARS-CoV-2 replication, likely through inhibition of Methyltransferase complexes (NSP10 / NSP16 and NSP10 / NSP14). The peptide of the present invention, P3, contains sequences corresponding to amino acids 89-96 of the non-structural protein 10 (NSP10) of SARS-CoV-2, with the only Cysteine modified to a Methionine. This peptide was made based on two previous designs P1 and P2, which constituted the amino acids 68-96 of the NSP10 protein of SARS-CoV-2.

The invention belongs to the technical field of African swine fever treatment, and particularly relates to novel application of a compound C75 in preventing or treating African swine fever. It is found that the compound C75 can inhibit transcription of an African swine fever virus structural protein p72 and reduce the expression level of virus proteins p72 and p30, and has the effect of inhibiting African swine fever virus infection; the compound can be used for preparing drugs or adjuvants for resisting African swine fever virus infection and inhibiting replication of African swine fever viruses.

The invention discloses a protein degradation product and application of non-structural protein NSs of rift valley fever virus or a coding gene of the non-structural protein NSs in preparation of the protein degradation product, and relates to the technical field of protein degradation. On the basis of the property that NSs and recombinant protein of the NSs can autonomously form a fiber-shaped high polymer structure, a degradation machine capable of degrading target protein is self-assembled, so that the specific and efficient degradation of the target protein is realized. Therefore, the new application of the non-structural protein NSs of the rift valley fever virus in targeted degradation of the protein is found, specific efficient degradation of the disease-related protein can be achieved, and the effect of treating diseases is expected to be achieved.

The application discloses a method for constructing a cell membrane fusion model induced by a novel coronavirus-like particle, and belongs to the technical field of biology. The method comprises the following steps: constructing a virus-like particle containing a SARS-CoV-2 spike protein gene and an RNA packaging sequence PS9, using HEK-293T cells as packaging cells, co-expressing structural proteins M, E, N and S protein, and realizing assembly of VLPs without replication ability. Subsequently, the VLPs are used to infect immortalized type II alveolar epithelial cells, S protein expression is induced and cell-cell membrane fusion is mediated without the need of BSL-3 laboratory conditions. The formation of fused giant cells can be directly observed through ZO-1 protein immunofluorescence staining, the model is stable, has high biological safety, and is repeatable in vitro. The application overcomes the safety risk of live virus infection and the authenticity problem of a transient transfection model, can be used for research on a SARS-CoV-2 virus membrane fusion mechanism, and has a good application prospect.

This invention discloses a SARS-CoV-2 virus-like particle, its preparation method, and its application. The genes encoding the structural proteins of the novel coronavirus include the S gene, M gene, or E gene. The nucleotide sequence of the S gene is shown in SEQ ID NO.1; the nucleotide sequence of the M gene is shown in SEQ ID NO.2; and the nucleotide sequence of the E gene is shown in SEQ ID NO.3. This invention provides, for the first time, a virus-like particle (VLP), which is self-assembled after expression of the three structural proteins S, M, and E of the SARS-CoV-2 virus via a baculovirus-insect cell expression system. This invention solves the problem of the current lack of a safe and effective VLP vaccine for the prevention and control of COVID-19. The VLP is suitable for mucosal immunization, improving the immunization effect while reducing vaccination and labor costs, and has potential economic benefits.

The invention discloses sphingomonas CCSM001 separated from human skin and capable of improving skin health and a metagen thereof, and belongs to the field of microbial technology and medicine. The sphingomonas CCSM001 provided by the invention has a good barrier function repairing effect and application prospect in the aspect of external use, and is specifically shown in that the activity of damaged HaCaT cells is improved in vitro, the gene level expression of FLG, IVL, AQP3, ZO-1, Occludin and CLDN is improved in the aspects of functional protein and structural protein after damage. The metagen prepared from the sphingomonas can be used for preparing cosmetics or medicines for repairing skin barriers, and has a huge application prospect.

The invention relates to an application of SLC15A3 in preparation of an anti-dengue virus drug, and discovers that a novel antiviral protein SLC15A3 has a novel application of efficiently targeting a dengue virus non-structural protein NS4A so as to inhibit the proliferation of a dengue virus in a host cell. The invention develops a new field of clinical application of the humanized antiviral protein in the field of antiviral prevention and treatment, so that a new thought and direction are provided for drug development of targeted dengue virus non-structural protein NS4A, a scientific basis is provided for development of anti-dengue virus drugs, and a new thought is provided for clinical antiviral treatment.

Provided herein are stoichiometric Gas Vesicle Expression Systems (GVES), sets of polynucleotide constructs, and related vectors, cells, compositions, and methods configured for robust expression of Gas Vesicle Gene Clusters (GVGCs) in mammalian cells, particularly primary and immune cells. The GVES comprises distinct gene modules for the primary structural protein (gvpA / B) and assembly factors (AF1, AF2), operably configured to achieve a stoichiometric expression ratio, quantified by Dosage Index (DI), wherein the gvpA / B module is expressed at least 2-fold higher than the AF1 and AF2 modules.

This invention discloses a method for preparing pet stem cell exosomes, belonging to the field of animal medicine technology. This invention treats stem cells with an inducing agent to secrete exosomes with high TFR expression on their surface. These exosomes specifically target the conserved region of the NS1 gene, a non-structural protein of the parvovirus family, allowing the internally loaded siRNA and trefoil factor 3 to target and enter infected cells, directly inhibiting viral replication at the gene level to treat feline panleukopenia virus (FPV) and canine parvovirus infections and alleviate sequelae. This invention solves the problems of existing technologies, such as difficulty in targeting, lack of specific drugs, reliance on intensive supportive care leading to a short treatment window, inability to directly clear the virus, risk of cross-infection, and potential long-term sequelae. It has the potential to be applied to the preparation of drugs for treating canine parvovirus and feline panleukopenia.

The invention relates to the technical field of skin care products, and particularly discloses an anti-aging polypeptide composition as well as a preparation method and application thereof. According to the anti-aging polypeptide composition disclosed by the invention, through a multi-target-point and multi-layer synergistic effect, efficient wrinkle smoothing, tightening and anti-aging are realized. The anti-aging polypeptide composition can act on a neuromuscular joint and a dermal matrix at the same time, and has double effects of immediate improvement and long-term repair. According to the anti-aging polypeptide composition, the active ingredients and the penetration enhancer are synergistic, and compared with exogenous supplement collagen, the anti-aging polypeptide composition can be effectively absorbed in a transdermal mode, enhance the regeneration capacity of autologous collagen, better regulate extracellular matrixes and improve the anti-aging effect of the composition, and the anti-aging polypeptide composition has the advantages that by endogenous stimulation of regeneration of structural protein such as skin collagen, the anti-aging effect of the anti-aging polypeptide composition is improved, and the anti-aging effect of the anti-aging polypeptide composition is improved. The problem of skin laxity and aging caused by loss of structural proteins such as skin collagen is thoroughly solved, and the efficient wrinkle smoothing and anti-aging effects are achieved.

Systems, compositions and methods for use of ice-structuring proteins (including antifreeze proteins and antifreeze glycoproteins) to prevent or reduce frost damage in seeds, seedlings, plants and plant products are disclosed. Compositions comprise one or more antifreeze proteins—derived from fish, insects, fungi, algae or bacteria—or modified variants thereof, and may include adjuvants, sugars, salts, oils, nanoparticles or microbial carriers. Delivery formats include foliar sprays, seed soaks or coatings, soil amendments, irrigation admixtures, nanoparticle-controlled release, and probiotic or endophytic microbes that secrete ice proteins in situ. Methods of application can lower freezing onset temperature, inhibit ice recrystallization to reduce tissue damage, and / or enhance plant cold-tolerance, depending on the chosen formulation. Representative formulations and experimental results (seed germination, seedling survival, reduced leaf freezing temperature and cryoprotection) are provided.

The application provides a compound truffle protein peptide and a preparation method thereof. The compound truffle protein peptide is mainly prepared from the following raw materials in mass fractions: 18-25 parts of cod collagen peptide, 1-2 parts of black truffle peptide, 2-4 parts of Pleurotus eryngii protein peptide, 3-10 parts of olive leaf juice, 2-9 parts of fig juice and 0.5-3 parts of probiotic powder. The compound truffle protein peptide is prepared by scientifically compounding rare fungus active peptide, high-quality structural protein peptide, natural plant antioxidant and intestinal probiotic, so as to achieve the effects of "nourishing skin, enhancing defense, radiating vitality and balancing internal environment".

The invention discloses staphylococcus epidermidis CCSM009 for repairing a skin barrier and a metagen of the staphylococcus epidermidis CCSM009, and belongs to the field of microbial technologies and medicines. The staphylococcus epidermidis CCSM009 and the metagen thereof provided by the invention have a good barrier function repairing effect and application prospect in the aspect of external use, and are specifically shown as follows: the activity of damaged HaCaT cells is improved in vitro, and the expression of gene levels and protein levels in the aspects of functional proteins and structural proteins after damage is improved; meanwhile, sphingomyelinase 1 and tissue kininolase 7 (KLK7) are improved, and it is clear that the bacterium performs up-regulation of skin barrier related proteins and enzymes through an AHR-OVOL1 pathway. Therefore, the metagen of the staphylococcus epidermidis CCSM009 has a huge application prospect in preparation of cosmetics or medicines for repairing the skin barrier.